<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> is neuroprotective in clinical and experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> studies, due in part to its ability to inhibit poly (<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase </plain></SENT>
<SENT sid="1" pm="."><plain>Previous preclinical data have shown that interference with poly (<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase signaling leads to sex-specific neuroprotection, reducing <z:hpo ids='HP_0001297'>stroke</z:hpo> injury only in males </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we show that <z:chebi fb="1" ids="50694">minocycline</z:chebi> is ineffective at reducing ischemic damage in females after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, likely due to effects on poly (<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase signaling </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical trials must consider possible sex differences in the response to neuroprotective agents, if we hope to translate promising therapies to <z:hpo ids='HP_0001297'>stroke</z:hpo> patients of both sexes </plain></SENT>
</text></document>